| 7.79 -3.69 (-32.14%) | 02-02 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.56 |
1-year : | 11.31 |
| Resists | First : | 8.19 |
Second : | 9.68 |
| Pivot price | 7.85 |
|||
| Supports | First : | 5.76 |
Second : | 4.8 |
| MAs | MA(5) : | 7.47 |
MA(20) : | 7.62 |
| MA(100) : | 8.08 |
MA(250) : | 16.71 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.2 |
D(3) : | 39.6 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 47 | Low : | 5.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FLGC ] has closed above bottom band by 1.1%. Bollinger Bands are 8.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.83 - 7.91 | 7.91 - 7.95 |
| Low: | 5.65 - 5.72 | 5.72 - 5.77 |
| Close: | 5.79 - 5.92 | 5.92 - 5.99 |
Flora Growth Corp., along with its various subsidiaries, operates as a global enterprise specializing in the cultivation, processing, and advancement of medicinal cannabis and its derived products. The company distributes these offerings to a broad international client base, including pharmacies, medical clinics, and cosmetic companies. Its extensive portfolio encompasses a range of activities and products: Cannabis and Derivatives: This core segment involves the production and supply of medical-grade cannabis oil, alongside a spectrum of cannabis-infused medical and wellness items. Health and Personal Care: They develop and market skincare and beauty products, plant-based pharmaceuticals, phytotherapeutics, and dietary supplements. Furthermore, their offerings include a wide array of cannabidiol (CBD) products like edibles (gummies), topical applications, tinctures, and vaping solutions, as well as general lifestyle wellness items such as bath and body products, pet care, and sports recovery aids. Ancillary and Lifestyle Products: Flora Growth designs and sells loungewear crafted from hemp-derived fabrics and provides accessories for cannabis consumption, personal storage, and travel, catering to both vape and dry herb users. Food and Beverages: The company's diversified operations also include the distribution of juices, gourmet chocolates (featuring exotic fruits coated in chocolate and chocolate bars), and dried fruits, beans, and pulp sourced from Amazonian regions. These items reach consumers through various retail channels, including supermarkets, discount stores, coffee shops, restaurants, and airports. They also manufacture, promote, and distribute other beverage products. Pharmaceutical Initiatives: Flora Growth is involved in creating and distributing pain relief formulations and is actively pursuing the development of a pharmaceutical cannabinoid formula intended for Sars-Cov-2 prevention. Their products are marketed under several distinct brands, including JustCBD, Vessel, Mind Naturals, Mambe, Stardog, Tonino Lamborghini, and Kalaya. Established in 2019, Flora Growth Corp. maintains its corporate headquarters in Toronto, Canada.
Wed, 28 Jan 2026
Flora Growth pulls planned stock sale, withdraws public offering - Stock Titan
Wed, 28 Jan 2026
Flora Growth Corp. Announces Withdrawal of Proposed Public Offering - TMX Newsfile
Tue, 27 Jan 2026
Flora Growth launches common shares public offering - Investing.com
Tue, 27 Jan 2026
Flora Growth to rename as ZeroStack, change ticker to ZSTK - Investing.com
Tue, 27 Jan 2026
Flora Growth’s ZeroStack shift includes 123M $0G AI tokens - Stock Titan
Tue, 13 Jan 2026
Flora Growth Corp. (NASDAQ:FLGC) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 47 (K) |
| EPS | -41.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 91.16 |
| Profit Margin | -27.8 % |
| Operating Margin | -33.5 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | -45.3 % |
| Qtrly Rev. Growth | 34.7 % |
| Gross Profit (p.s.) | 5.01 |
| Sales Per Share | 23.9 |
| EBITDA (p.s.) | -5.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.15 |
| PEG Ratio | 0 |
| Price to Book value | 0.06 |
| Price to Sales | 0.24 |
| Price to Cash Flow | -2.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|